Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 14 Myeloid 8 Sarcoma 1 NET 1 Lymphoid 1 Endocrine 1 Classical hematology 1 CNS 1 Breast 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 16 Magnetic Resonance Spectroscopy 14 gallium Ga 68 dotatate 9 Specimen Handling 8 Everolimus 8 pembrolizumab 7 cabozantinib 6 Cisplatin 6 fluorodopa F 18 5 Etoposide 5 trametinib 4 surufatinib 4 lanreotide 4 dabrafenib 4 cemiplimab 4 X-Rays 4 Temozolomide 4 Nivolumab 4 Lutetium-177 4 Lutetium 4 Fluorodeoxyglucose F18 4 Carboplatin 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 olaparib 3 lenvatinib 3 copper dotatate CU-64 3 Transurethral Resection of Prostate 3 Thyrotropin Alfa 3 Surveys and Questionnaires 3 Somatostatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × decitabine and cedazuridine drug combination × Endocrine × Clear all

NCT05178693 2025-11-24

LANTana

Imperial College London

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡